To determine the relationship between dependence on CDK4/6 activity and MYC dependence in breast cancer cells, a panel of twenty-six breast cancer cell lines was treated with either cyclin D1 siRNA or the CDK4/6 inhibitor PD0332991 (Additional file1: Figure S3). Here, MYC is linked to breast cancer.